Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab; Interferons direct Th2 cell reprogramming to generate a stable GATA-3+ T-bet+ cell subset with combined Th2 and Th1 cell functions; STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity; Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer; Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy; Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA; Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses; Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection; Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity; Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis; T cell-dependence of Lassa fever pathogenesis; Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors; Impaired antibody response causes persistence of prototypic T cell–contained virus; Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression; Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines; Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer; Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies; Association between immune-related adverse events during anti–PD-1 therapy and tumor mutational burden; Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC); CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
